Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 929-935

  Varga, Zsuzsanna ^a   Moelans, Cathy B ^b   Zuerrer Hardi, Ursina ^a   Ramach, Constanze ^a   Behnke, Silvia ^a   Kristiansen, Glen ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; Different probes; FISH; Topoisomerase 2A

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE 2A; UNCLASSIFIED DRUG;

ADULT; AGED; AMPLICON; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TOPOISOMERASE 2A GENE; TUMOR GENE;

EID: 85027921566     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/S10549-011-1873-8     Document Type: Article

References (27)

1. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181-189. doi:10.1007/sl0549-006-9492-5
2. Buzdar AU (2006) Topoisomerase Ilalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 24:2409-2411. doi:10.1200/JCO. 2006.05.9113
3. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA (2008) MLP Analyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cell Oncol 30:323-335
4. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluoro-uracil. Clin Cancer Res 8:1107-1116
5. Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ (2006) Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95:1334-1341. doi:10.1038/sj.bjc. 6603449
6. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR (2005) The incidence of topoisomerase Il-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 36:348-356. doi:10.1016/j.humpath.2005.01.016
7. Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS (2004) Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40:19-31. doi:10.1002/gcc.20019
8. Jarvinen TA, Liu ET (2006) Simultaneous amplification of HER-2 (ERBB2) and topoisomerase Ilalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6:579-602
9. Jarvinen TA, Liu ET (2003) Topoisomerase Ilalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology 14:309-313. doi:105[pii]
10. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150. doi:10.1002/(SICI)1098-2264(199910)26:2142
11. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase Ilalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847. doi:S0002-9440(10)64952-8[pii]
12. Kauraniemi P, Barlund M, Monni O, Kallioniemi A (2001) New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61:8235-8240
13. Kauraniemi P, Kallioniemi A (2006) Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 13:39-19. doi:13/l/39[pii]10.1677/erc.l. 01147
14. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdottir K, Olsen KE, Mouridsen H, Ejlertsen B (2005) Retrospective analysis of topoisomerase Ha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490. doi:10.1200/JCO.2005.11.007
15. Leo AD, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12:1134-1142. doi:10.1016/S1470- 2045(ll)70231-5
16. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23:1029-1039. doi:10.1038/modpathol.2010.84
17. Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ (2010) Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod Pathol 23:62-70. doi: 10.1038/modpathol.2009.136
18. Nielsen KV, Muller S, Moller S, Schonau A, Balslev E, Knoop AS, Ejlertsen B (2010) Aberrations of ERBB2 and TOP2A genes in breast cancer. Mol Oncol 4:161-168. doi:10.1016/j.molonc. 2009.11.001
19. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101:644-650. doi:10.1093/jnci/djp067
20. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schonau A, Overgaard J (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35-2
21. Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM (2006) Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res Treat 98:337-342. doi:10.1007/sl0549-006-9170-7
22. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ (2011) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29:859-867. doi:10.1200/JCO.2009.27.5644
23. Press MF SG, Buyse L, Bernstein L, Eiermann W, Pienkowski T, Bee V, Taupin H, Seelig S, Slamon DJ (2007) Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline-based chemotherapy. ASCO 2007 Annual Meeting, Abstract Nr. 524
24. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J (2006) Topoisomerase Ilalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian breast group trial 9401. J Clin Oncol 24:2428-2436. doi:10.1200/JCO.2005.02.9264
25. Tavassoli FA, Devilee P (eds) (2003) World Health Organization classification of tumours: Pathology and Genetics: tumours of the breast and female genital organs. IARC Press, Lyon
26. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF (2009) Outcome of patients with early stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-3886. doi:10.1200/JCO.2008.20.1566
27. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. doi:10.1200/JCO. 2006.09.2775